Johannes Gerardus Ramaekers

Johannes Gerardus Ramaekers

Auto-generated profile, based on publicly available information

Johannes Gerardus Ramaekers

Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, Netherlands

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2020 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
NMNatasha Mason
Natasha Mason
KKKim P. C. Kuypers
Kim P. C. Kuypers
FMF. Müller
F. Müller
JRJ. Reckweg
J. Reckweg
DTD. H. Y. Tse
D. H. Y. Tse
JRJ. G. Ramaekers
J. G. Ramaekers
There is growing interest in the therapeutic utility of psychedelic substances, like psilocybin, for disorders characterized by distortions of the self-experience, like depression. Accumulating preclinical evidence emphasizes the role of the glutamate system in the acute action of the drug on brain and behavior; however this has never been tested in humans. Following a double-blind, placebo-controlled, parallel group design, we utilized an ultra-high field multimodal brain imaging approach and demonstrated that psilocybin (0.17 mg/kg) induced region-dependent alterations in glutamate, which predicted distortions in the subjective experience of one’s self (ego dissolution). Whereas higher levels of medial prefrontal cortical glutamate were associated with negatively experienced ego dissolution, lower levels in hippocampal glutamate were associated with positively experienced ego dissolution. Such findings provide further insights into the underlying neurobiological mechanisms of the psychedelic, as well as the baseline, state. Importantly, they may also provide a neurochemical basis for therapeutic effects as witnessed in ongoing clinical trials.

13 August 2018 in Psychopharmacology
Verified
Journal Article
Open access
MUM. V. Uthaug
M. V. Uthaug
KOK. van Oorsouw
K. van Oorsouw
KKKim P. C. Kuypers
Kim P. C. Kuypers
MBM. van Boxtel
M. van Boxtel
NBN. J. Broers
N. J. Broers
JRJ. G. Ramaekers
J. G. Ramaekers
Rationale Ayahuasca is a psychotropic plant tea from South America used for religious purposes by indigenous people of the Amazon. Increasing evidence indicates that ayahuasca may have therapeutic potential in the treatment of mental health disorders and can enhance mindfulness-related capacities. Most research so far has focused on acute and sub-acute effects of ayahuasca on mental health-related parameters and less on long-term effects. Objectives The present study aimed to assess sub-acute and long-term effects of ayahuasca on well-being and cognitive thinking style. The second objective was to assess whether sub-acute and long-term effects of ayahuasca depend on the degree of ego dissolution that was experienced after consumption of ayahuasca. Results Ayahuasca ceremony attendants (N = 57) in the Netherlands and Colombia were assessed before, the day after, and 4 weeks following the ritual. Relative to baseline, ratings of depression and stress significantly decreased after the ayahuasca ceremony and these changes persisted for 4 weeks. Likewise, convergent thinking improved post-ayahuasca ceremony up until the 4 weeks follow-up. Satisfaction with life and several aspects of mindfulness increased the day after the ceremony, but these changes failed to reach significance 4 weeks after. Changes in affect, satisfaction with life, and mindfulness were significantly correlated to the level of ego dissolution experienced during the ayahuasca ceremony and were unrelated to previous experience with ayahuasca. Conclusion It is concluded that ayahuasca produces sub-acute and long-term improvements in affect and cognitive thinking style in non-pathological users. These data highlight the therapeutic potential of ayahuasca in the treatment of mental health disorders, such as depression.

13 April 2019 in Psychopharmacology
Verified
Journal Article
Open access
PDF file
MUM. V. Uthaug
M. V. Uthaug
RLR. Lancelotta
R. Lancelotta
KOK. van Oorsouw
K. van Oorsouw
KKK. P. C. Kuypers
K. P. C. Kuypers
NMNatasha Mason
Natasha Mason
JRJ. G. Ramaekers
J. G. Ramaekers
Background 5-methoxy-N,N-dimethyltryptamine (hereinafter referred to as 5-MeO-DMT) is a psychedelic substance found in the secretion from the parotoid glands of the Bufo alvarius toad. Inhalation of vapor from toad secretion containing 5-MeO-DMT has become popular in naturalistic settings as a treatment of mental health problems or as a means for spiritual exploration. However, knowledge of the effects of 5-MeO-DMT in humans is limited. Aims The first objective of this study was to assess sub-acute and long-term effects of inhaling vapor from dried toad secretion containing 5-MeO-DMT on affect and cognition. The second objective was to assess whether any changes were associated with the psychedelic experience. Methods Assessments at baseline, within 24 h and 4 weeks following intake, were made in 42 individuals who inhaled vapor from dried toad secretion at several European locations. Results Relative to baseline, ratings of satisfaction with life and convergent thinking significantly increased right after intake and were maintained at follow-up 4 weeks later. Ratings of mindfulness also increased over time and reached statistical significance at 4 weeks. Ratings of depression, anxiety, and stress decreased after the session, and reached significance at 4 weeks. Participants that experienced high levels of ego dissolution or oceanic boundlessness during the session displayed higher ratings of satisfaction with life and lower ratings of depression and stress. Conclusion A single inhalation of vapor from dried toad secretion containing 5-MeO-DMT produces sub-acute and long-term changes in affect and cognition in volunteers. These results warrant exploratory research into therapeutic applications of 5-MeO-DMT.

1 December 2020 in JAMA
Verified
Journal Article
Open access
PDF file
TAThomas R. Arkell
Thomas R. Arkell
FVFrederick Vinckenbosch
Frederick Vinckenbosch
RKRichard C. Kevin
Richard C. Kevin
ETEef L. Theunissen
Eef L. Theunissen
IMIain S. McGregor
Iain S. McGregor
JRJohannes G. Ramaekers
Johannes G. Ramaekers
Epidemiological studies have indicated that cannabis is associated with increased crash risk and culpability.1,2 Acute cannabis intoxication increases the standard deviation of lateral position (SDLP),3 an index of lane weaving, swerving, and overcorrecting that is a validated measure of alcohol- and drug-induced driving impairment.4

30 October 2010 in Psychopharmacology
Verified
Journal Article
Open access
PDF file
JRJohannes G. Ramaekers
Johannes G. Ramaekers
ETEef L. Theunissen
Eef L. Theunissen
MBMarjolein de Brouwer
Marjolein de Brouwer
STStefan W. Toennes
Stefan W. Toennes
MMManfred R. Moeller
Manfred R. Moeller
GKGerhold Kauert
Gerhold Kauert
Introduction Previous research has shown that heavy cannabis users develop tolerance to the impairing effects of Δ9-tetrahydrocannabinol (THC) on neurocognitive functions. Animal studies suggest that chronic cannabis consumption may also produce cross-tolerance for the impairing effects of alcohol, but supportive data in humans is scarce. Purpose The present study was designed to assess tolerance and cross-tolerance to the neurocognitive effects of THC and alcohol in heavy cannabis users. Methods Twenty-one heavy cannabis users participated in a double-blind, placebo-controlled, three-way study. Subjects underwent three alcohol-dosing conditions that were designed to achieve a steady blood alcohol concentration of about 0, 0.5, and 0.7 mg/ml during a 5-h time window. In addition, subjects smoked a THC cigarette (400 μg/kg) at 3 h post-onset of alcohol dosing during every alcohol condition. Performance tests were conducted repeatedly between 0 and 7 h after onset of drinking and included measures of perceptual motor control (critical tracking task), dual task processing (divided-attention task), motor inhibition (stop-signal task), and cognition (Tower of London). Results Alcohol significantly impaired critical tracking, divided attention, and stop-signal performance. THC generally did not affect task performance. However, combined effects of THC and alcohol on divided attention were bigger than those by alcohol alone. Conclusion In conclusion, the present study generally confirms that heavy cannabis users develop tolerance to the impairing effects of THC on neurocognitive task performance. Yet, heavy cannabis users did not develop cross-tolerance to the impairing effects of alcohol, and the presence of the latter even selectively potentiated THC effects on measures of divided attention.

8 March 2022 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
JRJohannes T. Reckweg
Johannes T. Reckweg
MUMalin V. Uthaug
Malin V. Uthaug
ASAttila Szabo
Attila Szabo
ADAlan K. Davis
Alan K. Davis
RLRafael Lancelotta
Rafael Lancelotta
JRJohannes G. Ramaekers
Johannes G. Ramaekers
5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) is a naturally occurring tryptamine that primarily acts as an agonist at the 5‐HT1A and 5‐HT2A receptors, whereby affinity for the 5‐HT1A subtype is highest. Subjective effects following 5‐MeO‐DMT administration include distortions in auditory and time perception, amplification of emotional states, and feelings of ego dissolution that usually are short‐lasting, depending on the route of administration. Individual dose escalation of 5‐MeO‐DMT reliably induces a “peak” experience, a state thought to be a core predictor of the therapeutic efficacy of psychedelics. Observational studies and surveys have suggested that single exposure to 5‐MeO‐DMT can cause rapid and sustained reductions in symptoms of depression, anxiety, and stress. 5‐MeO‐DMT also stimulates neuroendocrine function, immunoregulation, and anti‐inflammatory processes, which may contribute to changes in mental health outcomes. To date, only one clinical trial has been published on 5‐MeO‐DMT, demonstrating the safety of vaporized dosing up to 18 mg. Importantly, the rapid onset and short duration of the 5‐MeO‐DMT experience may render it more suitable for individual dose‐finding strategies compared with longer‐acting psychedelics. A range of biotech companies has shown an interest in the development of 5‐MeO‐DMT formulations for a range of medical indications, most notably depression. Commercial development will therefore be the most important resource for bringing 5‐MeO‐DMT to the clinic. However, fundamental research will also be needed to increase understanding of the neurophysiological and neural mechanisms that contribute to the potential clinical effects of 5‐MeO‐DMT and its sustainability and dissemination over time. Such studies are less likely to be conducted as part of drug development programs and are more likely to rely on independent, academic initiatives. image